Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
Purpose
This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgens, or male sex hormones, can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may help stop or reduce the growth of prostate cancer cell growth by blocking the attachment of androgen to its receptors on cancer cells, a mechanism similar to stopping the entrance of a key into its lock. Adding apalutamide to the usual hormone therapy and radiation therapy after surgery may stabilize prostate cancer and prevent it from spreading and extend time without disease spreading compared to the usual approach.
Conditions
- Prostate Adenocarcinoma
- Stage I Prostate Cancer AJCC v8
- Stage II Prostate Cancer AJCC v8
- Stage III Prostate Cancer AJCC v8
- Stage IVA Prostate Cancer AJCC v8
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- Male
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Pathologically (histologically) proven diagnosis of prostate adenocarcinoma. Any type of radical prostatectomy is permitted, including retropubic, perineal, laparoscopic or robotically assisted - Any T-stage is eligible (American Joint Committee on Cancer [AJCC] 8th edition [ed]) - Appropriate stage for study entry based on fluciclovine F-18 PET scan (FACBC, Axumin) F-18 prostate-specific membrane antigen (PSMA) PET (PyLarify) scan, Gallium-68 PSMA PET scan, flotufolastat F-18 PSMA PET scan (Posluma), or C-11 or F-18 Choline PET within 90 days prior to registration that is negative for distant metastatic (M1a, M1b, M1c) disease. For patients with PSA < 0.20 ng/mL at time of registration, PET scan is recommended but not required - Pathologically node positive disease with nodal involvement only in the pelvis in the prostatectomy specimen or nodal disease on imaging at time of recurrence (including external iliacs, internal iliacs, and/or obturator nodes); peri-prostatic and peri-rectal nodes can also be considered regional lymphadenopathy and are allowed - History/physical examination within 90 days prior to registration - Age >= 18 - Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 within 90 days prior to registration - Detectable PSA after radical prostatectomy. Detectable PSA is defined as serum PSA > 0 ng/mL at least 30 days after prostatectomy - Patients who have already started on post-prostatectomy GnRH agonist/antagonist for =< 180 days prior to registration are eligible (Note: patients who started on an oral antiandrogen are eligible if started =< 180 days and stopped prior to registration) - Hemoglobin >= 9.0 g/dL, independent of transfusion and/or growth factors (within 90 days prior to registration) - Platelet count >= 100,000 x 10^9/uL independent of transfusion and/or growth factors (within 90 days prior to registration) - Serum potassium >= 3.5 mmol/L within 90 days prior to registration - Creatinine clearance (CrCl) >= 30 mL/min estimated by Cockcroft-Gault (please use actual weight for calculation unless greater than 30% above ideal body weight then use the adjusted body weight) (within 90 days prior to registration) - Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (Note: In subjects with Gilbert's syndrome, if total bilirubin is > 1.5 x ULN, measure direct and indirect bilirubin and if direct bilirubin is =< 1.5 x ULN, subject is eligible) (within 90 days prior to registration) - Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) or alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional ULN (within 90 days prior to registration) - Serum albumin >= 3.0 g/dL (within 90 days prior to registration) - Discontinue or substitute concomitant medications known to lower the seizure threshold at least 30 days prior to registration - The patient must agree to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agree to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug - Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial and have a CD4 count >= 200 cells/microliter within 30 days prior to registration. Note: HIV testing is not required for eligibility for this protocol - For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy within 30 days prior to registration, if indicated. Note: HBV viral testing is not required for eligibility for this protocol - Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load within 30 days prior to registration - Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. Note: Any patient with a cancer (other than keratinocyte carcinoma or carcinoma in situ) who has no evidence of disease for < 3 years must contact the principal investigator, Ronald Chen, Doctor of Medicine (MD) - The patient or a legally authorized representative must provide study-specific informed consent prior to study entry
Exclusion Criteria
- Definitive radiologic evidence of metastatic disease (M1a, M1b or M1c) on molecular imaging (e.g. Fluciclovine F-18 PET, [FACBC, Axumin], F-18 PSMA PET [Pylarify], flotufolastat F-18 PSMA PET scan [Posluma], Gallium-68 PSMA PET scan or C-11 choline PET) - Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowed (completed > 3 years prior to registration) - Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields - Androgen deprivation therapy (ADT) prior to radical prostatectomy - Prior treatment with androgen receptor signaling inhibitor (including but not exclusive to a growing list of: abiraterone acetate, enzalutamide, apalutamide, darolutamide), unless started =< 180 days and stopped prior to registration, which is allowed - Current use of 5-alpha reductase inhibitor. NOTE: if the alpha reductase inhibitor is stopped prior to randomization the patient is eligible - History of any of the following: - Seizure or known condition that may pre-dispose to seizure (e.g. prior stroke within 1 year prior to registration, brain arteriovenous malformation, Schwannoma, meningioma, or other benign central nervous system [CNS] or meningeal disease which may require treatment with surgery or radiation therapy) - Severe or unstable angina, myocardial infarction, arterial or venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias within 12 months prior to registration - New York Heart Association functional classification III/IV (Note: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association functional classification.) - History of any condition that in the opinion of the investigator, would preclude participation in this study - Current evidence of any of the following: - Known gastrointestinal disorder affecting absorption of oral medications - Active uncontrolled infection - Presence of uncontrolled hypertension (persistent systolic blood pressure [BP] >= 160 mmHg or diastolic BP >= 100 mmHg). Subjects with a history of hypertension are allowed, provided that BP is controlled to within these limits by anti-hypertensive treatment - Any chronic medical condition requiring a higher dose of corticosteroid than 10 mg prednisone/prednisolone once daily - Baseline moderate and severe hepatic impairment (Child-Pugh Class B & C) - Inability to swallow oral pills - Any current condition that in the opinion of the investigator, would preclude participation in this study - Patients must not plan to participate in any other therapeutic clinical trials while receiving treatment on this study - Patients with inflammatory bowel disease
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Active Comparator Arm I (hormone therapy, radiation therapy) |
Patients receive standard of care hormone therapy per physician discretion for 24 months. Patients also undergo standard of care pelvis and prostate bed radiation therapy 5 days per week over 5-6 or 7-8 weeks beginning within 90 days of randomization in the absence of disease progression or unacceptable toxicity. Patients in both arms may undergo CT, MRI, bone scan, and PET as clinically indicated throughout the study. Patients may also undergo blood sample collection throughout the study. |
|
Experimental Arm II (hormone therapy, radiation therapy, apalutamide) |
Patients undergo standard of care hormone therapy and radiation therapy as in Arm I. Patients also receive apalutamide PO QD on days 1-90 of each cycle. Cycles repeat every 90 days for 8 cycles in the absence of disease progression or unacceptable toxicity. Patients in both arms may undergo CT, MRI, bone scan, and PET as clinically indicated throughout the study. Patients may also undergo blood sample collection throughout the study. |
|
Recruiting Locations
Phoenix 5308655, Arizona 5551752 85004
Little Rock 4119403, Arkansas 4099753 72205
Site Public Contact
501-686-8274
Anaheim 5323810, California 5332921 92806
Baldwin Park 5325866, California 5332921 91706
Bellflower 5327422, California 5332921 90706
Carmichael 5334336, California 5332921 95608
Carmichael 5334336, California 5332921 95608
Elk Grove 5346111, California 5332921 95758
Fontana 5349755, California 5332921 92335
Greenbrae 5354013, California 5332921 94904
Site Public Contact
415-925-7325
Harbor City 5355325, California 5332921 90710
Irvine 5359777, California 5332921 92618
Long Beach 5367929, California 5332921 90822
Site Public Contact
562-826-8000
Los Angeles 5368361, California 5332921 90027
Los Angeles 5368361, California 5332921 90034
Los Angeles 5368361, California 5332921 90095
Site Public Contact
888-798-0719
Ontario 5379439, California 5332921 91761
Panorama City 5380932, California 5332921 91402
Riverside 5387877, California 5332921 92505
Rocklin 5388319, California 5332921 95765
Sacramento 5389489, California 5332921 95816
Sacramento 5389489, California 5332921 95817
Site Public Contact
916-734-3089
San Diego 5391811, California 5332921 92120
San Francisco 5391959, California 5332921 94115
Site Public Contact
877-827-3222
San Francisco 5391959, California 5332921 94143
Site Public Contact
877-827-3222
San Francisco 5391959, California 5332921 94158
San Marcos 5392368, California 5332921 92078
Woodland 5410430, California 5332921 95695
Woodland Hills 5410438, California 5332921 91367
Millville 4143696, Delaware 4142224 19967
Newark 4143861, Delaware 4142224 19713
Newark 4143861, Delaware 4142224 19713
Newark 4143861, Delaware 4142224 19718
Rehoboth Beach 4144284, Delaware 4142224 19971
Washington D.C. 4140963, District of Columbia 4138106 20037
Site Public Contact
202-741-2210
Aventura 4146429, Florida 4155751 33180
Site Public Contact
954-461-2180
Coral Gables 4151871, Florida 4155751 33146
Site Public Contact
305-243-2647
Deerfield Beach 4153071, Florida 4155751 33442
Site Public Contact
305-243-2647
Doral 4153471, Florida 4155751 33166
Miami 4164138, Florida 4155751 33136
Site Public Contact
305-243-2647
Miami 4164138, Florida 4155751 33176
Site Public Contact
305-243-2647
Plantation 4168782, Florida 4155751 33324
Site Public Contact
305-243-2647
Tampa 4174757, Florida 4155751 33606
Atlanta 4180439, Georgia 4197000 30303
Site Public Contact
404-778-1868
Atlanta 4180439, Georgia 4197000 30308
Atlanta 4180439, Georgia 4197000 30308
Site Public Contact
888-946-7447
Atlanta 4180439, Georgia 4197000 30322
Site Public Contact
404-778-1868
Atlanta 4180439, Georgia 4197000 30342
Site Public Contact
404-851-7115
Decatur 4191124, Georgia 4197000 30033
Johns Creek 6331909, Georgia 4197000 30097
Alton 4232679, Illinois 4896861 62002
Site Public Contact
618-463-7323
Aurora 4883817, Illinois 4896861 60504
Aurora 4883817, Illinois 4896861 60506
Barrington 4884116, Illinois 4896861 60010
Site Public Contact
847-842-4847
Bloomington 4885164, Illinois 4896861 61704
Canton 4831990, Illinois 4896861 61520
Carthage 4886716, Illinois 4896861 62321
Chicago 4887398, Illinois 4896861 60611
Chicago 4887398, Illinois 4896861 60612
Site Public Contact
312-355-3046
Chicago 4887398, Illinois 4896861 60637
Chicago 4887398, Illinois 4896861 60657
Site Public Contact
773-296-5360
Crystal Lake 4889229, Illinois 4896861 60014
Danville 4889426, Illinois 4896861 61832
Decatur 4236895, Illinois 4896861 62526
DeKalb 4889553, Illinois 4896861 60115
Dixon 4889959, Illinois 4896861 61021
Site Public Contact
815-285-7800
Downers Grove 4890119, Illinois 4896861 60515
Effingham 4237727, Illinois 4896861 62401
Effingham 4237727, Illinois 4896861 62401
Elgin 4890864, Illinois 4896861 60123
Site Public Contact
847-429-2907
Elmhurst 4891010, Illinois 4896861 60126
Eureka 4891310, Illinois 4896861 61530
Evanston 4891382, Illinois 4896861 60201
Site Public Contact
847-570-2109
Galesburg 4893392, Illinois 4896861 61401
Geneva 4893591, Illinois 4896861 60134
Glenview 4893886, Illinois 4896861 60026
Site Public Contact
847-570-2109
Harvey 4895298, Illinois 4896861 60426
Hazel Crest 4895416, Illinois 4896861 60429
Site Public Contact
708-799-9995
Highland Park 4895876, Illinois 4896861 60035
Site Public Contact
847-570-2109
Kewanee 4898433, Illinois 4896861 61443
Libertyville 4899739, Illinois 4896861 60048
Libertyville 4899739, Illinois 4896861 60048
Macomb 4900817, Illinois 4896861 61455
Mattoon 4244099, Illinois 4896861 61938
Maywood 4901514, Illinois 4896861 60153
Site Public Contact
708-226-4357
Naperville 4903279, Illinois 4896861 60540
Site Public Contact
630-646-6075
New Lenox 4903535, Illinois 4896861 60451
O'Fallon 4245926, Illinois 4896861 62269
Oak Brook 4904277, Illinois 4896861 60523
Oak Lawn 4904365, Illinois 4896861 60453-2699
Site Public Contact
800-323-8622
Orland Park 4904937, Illinois 4896861 60462
Orland Park 4904937, Illinois 4896861 60462
Ottawa 4905006, Illinois 4896861 61350
Palos Heights 4905259, Illinois 4896861 60463
Park Ridge 4905367, Illinois 4896861 60068
Site Public Contact
847-384-3621
Pekin 4905599, Illinois 4896861 61554
Pekin 4905599, Illinois 4896861 61554
Peoria 4905687, Illinois 4896861 61615
Peoria 4905687, Illinois 4896861 61615
Peoria 4905687, Illinois 4896861 61636
Peoria 4905687, Illinois 4896861 61637
Peru 4905770, Illinois 4896861 61354
Peru 4905770, Illinois 4896861 61354
Site Public Contact
815-664-4141
Princeton 4906818, Illinois 4896861 61356
Shiloh 4249910, Illinois 4896861 62269
Springfield 4250542, Illinois 4896861 62702
Site Public Contact
217-545-7929
Springfield 4250542, Illinois 4896861 62702
Site Public Contact
800-444-7541
Springfield 4250542, Illinois 4896861 62781
Urbana 4914570, Illinois 4896861 61801
Warrenville 4915525, Illinois 4896861 60555
Washington 4915545, Illinois 4896861 61571
Richmond 4263681, Indiana 4921868 47374
Ames 4846834, Iowa 4862182 50010
Ankeny 4846960, Iowa 4862182 50023
Site Public Contact
515-241-3305
Carroll 4850478, Iowa 4862182 51401
Cedar Rapids 4850751, Iowa 4862182 52403
Site Public Contact
319-365-4673
Cedar Rapids 4850751, Iowa 4862182 52403
Site Public Contact
319-363-2690
Des Moines 4853828, Iowa 4862182 50309
Site Public Contact
515-241-6727
Des Moines 4853828, Iowa 4862182 50309
Site Public Contact
515-241-3305
Des Moines 4853828, Iowa 4862182 50314
Site Public Contact
515-282-2200
Des Moines 4853828, Iowa 4862182 50314
Des Moines 4853828, Iowa 4862182 50316
Site Public Contact
515-241-8704
West Des Moines 4881346, Iowa 4862182 50266-7700
Site Public Contact
515-343-1000
Kansas City 4273837, Kansas 4273857 66160
Olathe 4276614, Kansas 4273857 66061
Overland Park 4276873, Kansas 4273857 66210
Salina 4278890, Kansas 4273857 67401
Topeka 4280539, Kansas 4273857 66606
Site Public Contact
785-295-8000
Westwood 4281639, Kansas 4273857 66205
Baton Rouge 4315588, Louisiana 4331987 70805
Baton Rouge 4315588, Louisiana 4331987 70808
Baton Rouge 4315588, Louisiana 4331987 70809
Metairie 4333177, Louisiana 4331987 70002
Site Public Contact
504-584-6990
Metairie 4333177, Louisiana 4331987 70006
Metairie 4333177, Louisiana 4331987 70006
New Orleans 4335045, Louisiana 4331987 70112
New Orleans 4335045, Louisiana 4331987 70121
Brewer 4959233, Maine 4971068 04412
Site Public Contact
800-987-3005
Boston 4930956, Massachusetts 6254926 02114
Site Public Contact
877-726-5130
Boston 4930956, Massachusetts 6254926 02115
Site Public Contact
617-724-5200
Boston 4930956, Massachusetts 6254926 02215
Site Public Contact
877-442-3324
Ann Arbor 4984247, Michigan 5001836 48106
Brighton 4986994, Michigan 5001836 48114
Canton 4987990, Michigan 5001836 48188
Chelsea 4988628, Michigan 5001836 48118
Detroit 4990729, Michigan 5001836 48202
Flint 4992982, Michigan 5001836 48532
Flint 4992982, Michigan 5001836 48532
Lansing 4998830, Michigan 5001836 48910
Lansing 4998830, Michigan 5001836 48912
Lansing 4998830, Michigan 5001836 48912
Livonia 4999837, Michigan 5001836 48154
Mount Clemens 5002656, Michigan 5001836 48043
Owosso 5004792, Michigan 5001836 48867
Burnsville 5019767, Minnesota 5037779 55337
Coon Rapids 5022025, Minnesota 5037779 55433
Edina 5025264, Minnesota 5037779 55435
Maple Grove 5036493, Minnesota 5037779 55369
Maplewood 5036588, Minnesota 5037779 55109
Maplewood 5036588, Minnesota 5037779 55109
Minneapolis 5037649, Minnesota 5037779 55407
Minneapolis 5037649, Minnesota 5037779 55415
Monticello 5038045, Minnesota 5037779 55362
Robbinsdale 5043439, Minnesota 5037779 55422
Saint Cloud 5044407, Minnesota 5037779 56303
Saint Louis Park 5045021, Minnesota 5037779 55416
Saint Paul 5045360, Minnesota 5037779 55101
Saint Paul 5045360, Minnesota 5037779 55102
Shakopee 5046997, Minnesota 5037779 55379
Stillwater 5048814, Minnesota 5037779 55082
Waconia 5051640, Minnesota 5037779 55387
Willmar 5052916, Minnesota 5037779 56201
Woodbury 5053358, Minnesota 5037779 55125
Cape Girardeau 4379966, Missouri 4398678 63703
City of Saint Peters 4407237, Missouri 4398678 63376
Columbia 4381982, Missouri 4398678 65212
Site Public Contact
573-882-7440
Creve Coeur 4382837, Missouri 4398678 63141
Kansas City 4393217, Missouri 4398678 64154
Lee's Summit 4394870, Missouri 4398678 64064
North Kansas City 4400860, Missouri 4398678 64116
St Louis 4407066, Missouri 4398678 63110
St Louis 4407066, Missouri 4398678 63129
St Louis 4407066, Missouri 4398678 63136
St Louis 4407066, Missouri 4398678 63141
Site Public Contact
314-251-7066
Billings 5640350, Montana 5667009 59101
Great Falls 5655240, Montana 5667009 59405
Lincoln 5072006, Nebraska 5073708 68516
Henderson 5505411, Nevada 5509151 89052
Henderson 5505411, Nevada 5509151 89052
Las Vegas 5506956, Nevada 5509151 89102
Las Vegas 5506956, Nevada 5509151 89106
Las Vegas 5506956, Nevada 5509151 89119
Las Vegas 5506956, Nevada 5509151 89128
Las Vegas 5506956, Nevada 5509151 89128
Las Vegas 5506956, Nevada 5509151 89144
Las Vegas 5506956, Nevada 5509151 89144
Las Vegas 5506956, Nevada 5509151 89144
Las Vegas 5506956, Nevada 5509151 89148
Las Vegas 5506956, Nevada 5509151 89148
Las Vegas 5506956, Nevada 5509151 89148
Las Vegas 5506956, Nevada 5509151 89169
Reno 5511077, Nevada 5509151 89502
Concord 5084868, New Hampshire 5090174 03301
Site Public Contact
603-224-2556
Manchester 5089178, New Hampshire 5090174 03103
Site Public Contact
800-339-6484
Basking Ridge 5095409, New Jersey 5101760 07920
Site Public Contact
212-639-7592
Camden 4501018, New Jersey 5101760 08103
Site Public Contact
856-325-6757
Livingston 5100572, New Jersey 5101760 07039
Middletown 5101170, New Jersey 5101760 07748
Site Public Contact
212-639-7592
Montvale 5101361, New Jersey 5101760 07645
Site Public Contact
212-639-7592
New Brunswick 5101717, New Jersey 5101760 08903
Site Public Contact
732-235-7356
Newark 5101798, New Jersey 5101760 07101
Site Public Contact
732-235-7356
Somerville 5104774, New Jersey 5101760 08876
Voorhees Township 5105860, New Jersey 5101760 08043
Site Public Contact
856-325-6757
Canandaigua 5111405, New York 5128638 14424
Site Public Contact
585-396-6161
Commack 5113412, New York 5128638 11725
Site Public Contact
212-639-7592
Forest Hills 5117575, New York 5128638 11375
Site Public Contact
718-520-6620
Harrison 5120095, New York 5128638 10604
Site Public Contact
212-639-7592
Lake Success 5123853, New York 5128638 11042
Site Public Contact
516-734-8896
Middletown 5126842, New York 5128638 10940
New York 5128581, New York 5128638 10065
Site Public Contact
212-639-7592
Rego Park 5133640, New York 5128638 11374
Site Public Contact
718-312-3446
Rochester 5134086, New York 5128638 14606
Site Public Contact
585-758-7877
Rochester 5134086, New York 5128638 14620
Site Public Contact
585-341-8113
Rochester 5134086, New York 5128638 14642
Site Public Contact
585-275-5830
Uniondale 5141927, New York 5128638 11553
Site Public Contact
212-639-7592
Webster 5143495, New York 5128638 14580
Cary 4459467, North Carolina 4482348 27518
Durham 4464368, North Carolina 4482348 27710
Site Public Contact
888-275-3853
Raleigh 4487042, North Carolina 4482348 27609
Winston-Salem 4499612, North Carolina 4482348 27157
Site Public Contact
336-713-6771
Akron 5145476, Ohio 5165418 44307
Centerville 4508204, Ohio 5165418 45459
Cincinnati 4508722, Ohio 5165418 45219
Cleveland 5150529, Ohio 5165418 44111
Cleveland 5150529, Ohio 5165418 44195
Columbus 4509177, Ohio 5165418 43210
Dayton 4509884, Ohio 5165418 45409
Dayton 4509884, Ohio 5165418 45409
Site Public Contact
937-276-8320
Dayton 4509884, Ohio 5165418 45415
Findlay 5153924, Ohio 5165418 45840
Franklin 4512203, Ohio 5165418 45005-1066
Mansfield 5161723, Ohio 5165418 44906
Mayfield Heights 5162188, Ohio 5165418 44124
Sandusky 5170691, Ohio 5165418 44870
Strongsville 5173237, Ohio 5165418 44136
Troy 5174358, Ohio 5165418 45373
West Chester 4520522, Ohio 5165418 45069
Wooster 5177358, Ohio 5165418 44691
Oklahoma City 4544349, Oklahoma 4544379 73104
Altoona 5178195, Pennsylvania 6254927 16601
Beaver 5179446, Pennsylvania 6254927 15009
Carlisle 5183234, Pennsylvania 6254927 17015
Chadds Ford 4557084, Pennsylvania 6254927 19317
Erie 5188843, Pennsylvania 6254927 16505
Farrell 5189377, Pennsylvania 6254927 16121
Greensburg 5192029, Pennsylvania 6254927 15601
Site Public Contact
724-838-1900
Harrisburg 5192726, Pennsylvania 6254927 17109
Hershey 5193342, Pennsylvania 6254927 17033-0850
Indiana 5194868, Pennsylvania 6254927 15701
Johnstown 5195561, Pennsylvania 6254927 15901
Site Public Contact
814-534-4724
McKeesport 5200499, Pennsylvania 6254927 15132
Site Public Contact
412-647-8073
Mechanicsburg 5200657, Pennsylvania 6254927 17050
Monroeville 5201734, Pennsylvania 6254927 15146
Moon Township 5201821, Pennsylvania 6254927 15108
Pittsburgh 5206379, Pennsylvania 6254927 15213
Site Public Contact
412-647-2811
Pittsburgh 5206379, Pennsylvania 6254927 15215
Site Public Contact
412-784-4900
Pittsburgh 5206379, Pennsylvania 6254927 15232
Site Public Contact
412-621-2334
Pittsburgh 5206379, Pennsylvania 6254927 15237
Site Public Contact
412-367-6454
Pittsburgh 5206379, Pennsylvania 6254927 15243
Site Public Contact
412-502-3920
Seneca 5211432, Pennsylvania 6254927 16346
Site Public Contact
814-676-7900
Uniontown 4561859, Pennsylvania 6254927 15401
Site Public Contact
724-437-2503
Washington 5218069, Pennsylvania 6254927 15301
West Chester 4562144, Pennsylvania 6254927 19380
West Reading 5218867, Pennsylvania 6254927 19611
Site Public Contact
610-988-9323
York 4562407, Pennsylvania 6254927 17408
Site Public Contact
717-724-6760
Mitchell 5229794, South Dakota 5769223 57301
Sioux Falls 5231851, South Dakota 5769223 57105
Dallas 4684888, Texas 4736286 75235
Dallas 4684888, Texas 4736286 75390
Fort Worth 4691930, Texas 4736286 76104
Fort Worth 4691930, Texas 4736286 76104
Richardson 4722625, Texas 4736286 75080
Mechanicsville 4772566, Virginia 6254928 23116
Midlothian 4772943, Virginia 6254928 23114
Richmond 4781708, Virginia 6254928 23230
Richmond 4781708, Virginia 6254928 23235
Richmond 4781708, Virginia 6254928 23298
Charleston 4801859, West Virginia 4826850 25304
Site Public Contact
304-388-9944
Antigo 5244010, Wisconsin 5279468 54409
Appleton 5244080, Wisconsin 5279468 54911
Burlington 5247214, Wisconsin 5279468 53105
Eau Claire 5251436, Wisconsin 5279468 54701
Germantown 5254218, Wisconsin 5279468 53022
Grafton 5254739, Wisconsin 5279468 53024
Green Bay 5254962, Wisconsin 5279468 54301
Site Public Contact
920-435-8326
Green Bay 5254962, Wisconsin 5279468 54311
Kenosha 5258393, Wisconsin 5279468 53142
Marinette 5261852, Wisconsin 5279468 54143
Marshfield 5261969, Wisconsin 5279468 54449
Menomonee Falls 5262630, Wisconsin 5279468 53051
Site Public Contact
262-257-5100
Milwaukee 5263045, Wisconsin 5279468 53209
Milwaukee 5263045, Wisconsin 5279468 53215
Milwaukee 5263045, Wisconsin 5279468 53226
Site Public Contact
414-805-3666
Milwaukee 5263045, Wisconsin 5279468 53233
Minocqua 5263156, Wisconsin 5279468 54548
New Richmond 5264475, Wisconsin 5279468 54017
Oak Creek 5265228, Wisconsin 5279468 53154
Site Public Contact
414-805-0505
Oshkosh 5265838, Wisconsin 5279468 54904
Racine 5268249, Wisconsin 5279468 53406
Rhinelander 5268720, Wisconsin 5279468 54501
Rice Lake 5268798, Wisconsin 5279468 54868
Sheboygan 5272893, Wisconsin 5279468 53081
Stevens Point 5274644, Wisconsin 5279468 54481
Stevens Point 5274644, Wisconsin 5279468 54482
Summit, Wisconsin 5279468 53066
Wausau 5278120, Wisconsin 5279468 54401
Site Public Contact
877-405-6866
Wauwatosa 5278159, Wisconsin 5279468 53226
West Allis 5278420, Wisconsin 5279468 53227
West Bend 5278422, Wisconsin 5279468 53095
Site Public Contact
414-805-0505
Weston 5278693, Wisconsin 5279468 54476
Wisconsin Rapids 5279436, Wisconsin 5279468 54494
Site Public Contact
715-422-7718
More Details
- NCT ID
- NCT04134260
- Status
- Recruiting
- Sponsor
- NRG Oncology
Detailed Description
PRIMARY OBJECTIVE: I. Compare metastasis-free survival (MFS) of salvage radiation therapy (RT) and gonadotropin releasing hormone (GnRH) agonist/antagonist versus (vs.) RT/GnRH agonist/antagonist with apalutamide for patients with pathologic node-positive prostate cancer after radical prostatectomy with detectable prostate-specific antigen (PSA). SECONDARY OBJECTIVES: I. Compare health-related quality of life (Expanded Prostate Cancer Index Composite [EPIC]-26, EuroQol [EQ]-5 Dimension [D]-5 Level [L], Brief Pain Inventory, Patient Reported Outcome Measurement Information System [PROMIS]-Fatigue) among the treatment arms. II. Compare overall survival, biochemical progression-free survival, time to local-regional progression, time to castrate resistance, and cancer-specific survival among the treatment arms. III. Compare the short-term and long-term treatment-related adverse events among the treatment arms. EXPLORATORY OBJECTIVES: I. Validate Decipher score for an exclusively node-positive population and use additional genomic information from Affymetrix Human Exon 1.0st array to develop and validate novel prognostic and predictive biomarkers. II. Validate the PAM50-based classification of prostate cancer into luminal A, luminal B, and basal subtypes as prognostic markers and determine whether the luminal B subtype is a predictive marker for having a larger improvement in outcome from the addition of apalutamide. III. To optimize quality assurance methodologies and processes for radiotherapy and imaging with machine learning strategies. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive standard of care hormone therapy per physician discretion for 24 months. Patients also undergo standard of care pelvis and prostate bed radiation therapy 5 days per week over 5-6 or 7-8 weeks beginning within 90 days of randomization in the absence of disease progression or unacceptable toxicity. ARM II: Patients undergo standard of care hormone therapy and radiation therapy as in Arm I. Patients also receive apalutamide orally (PO) once daily (QD) on days 1-90 of each cycle. Cycles repeat every 90 days for 8 cycles in the absence of disease progression or unacceptable toxicity. Patients in both arms may undergo computed tomography (CT), magnetic resonance imaging (MRI), bone scan, and positron emission tomography (PET) as clinically indicated throughout the study. Patients may also undergo blood sample collection throughout the study. After completion of study treatment, patients are followed up every 6 months for 3 years, then annually thereafter.